La Jolla Pharmaceutical Co (LJPC) 10-K Annual Report Mon Mar 08 2021

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
Document and Entity Information - USD ($) $ in Millions	Dec. 31, 2020	Feb. 08, 2021	Jun. 30, 2020
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--12-31
Entity File Number	1-36282
Entity Registrant Name	LA JOLLA PHARMACEUTICAL COMPANY
Entity Incorporation, State or Country Code	CA
Entity Tax Identification Number	33-0361285
Entity Address, Address Line One	201 Jones Road
Entity Address, Address Line Two	Suite 400
Entity Address, City or Town	Waltham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02451
City Area Code	617
Local Phone Number	715-3600
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	LJPC
Security Exchange Name	NASDAQ
Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Shell Company	false
Entity Common Stock, Shares Outstanding		27,428,407
Entity Central Index Key	0000920465
Amendment Flag	false
Entity Public Float			$ 78.0
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
ICFR Auditor Attestation Flag	false
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s definitive proxy statement for its 2021 Annual Meeting of Shareholders, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant’s fiscal year ended December 31, 2020, are incorporated by reference into Part III of this Annual Report on Form 10-K.

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/920465/000156459021011366/ljpc-10k_20201231.htm

View differences made from one year to another to evaluate La Jolla Pharmaceutical Co's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by La Jolla Pharmaceutical Co.

Continue

Assess how La Jolla Pharmaceutical Co's management team is paid from their Annual Proxy

La Jolla Pharmaceutical Co's Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Rating
Learn More

Filter by Sentiment:

All

Positive

Negative

Filter by Category:

All

Revenue

M & A

Financial

Other

Filter by Subcategory:

All

Geography

Expense

Cash Flow

Product

Income

Other

Inside La Jolla Pharmaceutical Co's 10-K Annual Report:

Other - Other Highlight
La Jolla is entitled to receive an upfront cash payment of $22.5 million plus potential commercial milestone payments of up to $109.5 million and double-digit tiered royalty payments.

Revenue - Geography Highlight
On January 12, 2021, La Jolla Pharmaceutical Company and certain of its wholly owned subsidiaries, including La Jolla Pharma, LLC and Tetraphase, entered into an exclusive licensing agreement ("PAION License") with PAION AG and its wholly owned subsidiary (collectively, "PAION") to commercialize GIAPREZA and XERAVA in the European Economic Area, the United Kingdom and Switzerland whereby La Jolla is entitled to receive an upfront cash payment of $22.5 million plus potential commercial milestone payments of up to $109.5 million and double-digit tiered royalty payments.
M & A - Other Highlight
The increase in cash used for investing activities resulted primarily from the acquisition of Tetraphase, net of cash, cash equivalents and restricted cash acquired, partially offset by proceeds from the sale of property and equipment.
Other - Other Highlight
The increase in cash provided by financing activities was primarily the result of net proceeds from issuance of common stock under employee stock plans.
Financial - Expense Highlight
We expect our research and development expense to significantly decrease in the near term.
Financial - Expense
During the year ended December...Read more
Financial - Expense
We expect selling, general and...Read more
M & A - Other
For the three and twelve...Read more
Financial - Cash Flow
In the event that such...Read more
Revenue - Product
The Company is eligible to...Read more
M & A - Other
On July 28, 2020, La...Read more
Financial - Expense
Interest expense and the amortization...Read more
Financial - Expense
Personnel-related expense includes expense related...Read more
Revenue - Product
For the three and twelve...Read more
M & A - Other
Intangible Assets Intangible assets acquired...Read more
Financial - Expense
Personnel-related expense includes expense related...Read more
Revenue - Product
To determine revenue recognition for...Read more
Other - Other
Net cash used for operating...Read more
Other - Other
Intangible assets with a definite...Read more
M & A - Other
Any excess of the fair...Read more
Revenue - Product
For each product covered by...Read more
Financial - Expense
Changes in interest expense resulting...Read more
Revenue - Product
Revenue is recognized in an...Read more
Financial - Expense
During the year ended December...Read more
M & A - Other
This method requires, among other...Read more
Other - Other
The financial terms of our...Read more
M & A - Other
Intangible assets acquired in a...Read more
Other - Other
On a pro forma basis,...Read more
Other - Other
On a pro forma basis,...Read more
Other - Other
However, if that is the...Read more
M & A - Other
Contingent consideration liabilities are recognized...Read more
Financial - Income
Other income (expense), net consists...Read more

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Material Contracts, Statements, Certifications & more

La Jolla Pharmaceutical Co provided additional information to their SEC Filing as exhibits

Exhibit 10.6: Material Contract

Exhibit 10.7: Material Contract

Exhibit 10.8: Material Contract

Exhibit 10.9: Material Contract

Exhibit 10.10: Material Contract

Exhibit 10.11: Material Contract

Exhibit 10.13: Material Contract

Exhibit 21.1: Subsidaries Of The Registrant

Exhibit 23.1: Consents Of Experts And Counsel

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Exhibit 32.2: Section 1350 Certification

Ticker: LJPC
CIK: 920465
Form Type: 10-K Annual Report
Accession Number: 0001564590-21-011366
Submitted to the SEC: Mon Mar 08 2021 8:30:48 AM EST
Accepted by the SEC: Mon Mar 08 2021
Period: Thursday, December 31, 2020
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/ljpc/0001564590-21-011366.htm

La Jolla Pharmaceutical Co (LJPC) SEC Filing 10-K Annual report for the fiscal year ending Thursday, December 31, 2020

SEC Filings

LJPC Valuations

LJPC Annual Reports

LJPC Quarterly Reports

LJPC Corporate News